CO2020012563A2 - Proteínas de fusión del factor de diferenciación de crecimiento 15 - Google Patents
Proteínas de fusión del factor de diferenciación de crecimiento 15Info
- Publication number
- CO2020012563A2 CO2020012563A2 CONC2020/0012563A CO2020012563A CO2020012563A2 CO 2020012563 A2 CO2020012563 A2 CO 2020012563A2 CO 2020012563 A CO2020012563 A CO 2020012563A CO 2020012563 A2 CO2020012563 A2 CO 2020012563A2
- Authority
- CO
- Colombia
- Prior art keywords
- fusion proteins
- differentiation factor
- growth differentiation
- gdf15
- region
- Prior art date
Links
- 102000000597 Growth Differentiation Factor 15 Human genes 0.000 title 1
- 108010041834 Growth Differentiation Factor 15 Proteins 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 abstract 5
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 abstract 5
- 230000004927 fusion Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
En el presente documento se proporcionan molécula de Fcs de GDF15. En algunas realizaciones, la molécula de Fc de GDF15 es una fusión GDF15-Fc, en la que se fusiona una región de GDF15 a una región de Fc. En algunas realizaciones, la región de GDF15 está fusionada a la región de Fc mediante un enlazador. También, en el presente documento se proporcionan métodos para crear y usar molécula de Fcs de GDF15
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862655108P | 2018-04-09 | 2018-04-09 | |
PCT/US2019/026369 WO2019199685A1 (en) | 2018-04-09 | 2019-04-08 | Growth differentiation factor 15 fusion proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2020012563A2 true CO2020012563A2 (es) | 2020-10-30 |
Family
ID=66251865
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2020/0012563A CO2020012563A2 (es) | 2018-04-09 | 2020-10-08 | Proteínas de fusión del factor de diferenciación de crecimiento 15 |
Country Status (23)
Country | Link |
---|---|
US (3) | US12054527B2 (es) |
EP (1) | EP3773656A1 (es) |
JP (2) | JP7058670B2 (es) |
KR (1) | KR20200140878A (es) |
CN (1) | CN111954537A (es) |
AR (1) | AR114476A1 (es) |
AU (1) | AU2019253462A1 (es) |
BR (1) | BR112020020823A2 (es) |
CA (1) | CA3096097A1 (es) |
CL (1) | CL2020002585A1 (es) |
CO (1) | CO2020012563A2 (es) |
CR (1) | CR20200510A (es) |
EA (1) | EA202092419A1 (es) |
IL (1) | IL277842A (es) |
JO (1) | JOP20200258A1 (es) |
MA (1) | MA52205A (es) |
MX (1) | MX2020010659A (es) |
PE (1) | PE20201350A1 (es) |
PH (1) | PH12020551655A1 (es) |
SG (1) | SG11202009884YA (es) |
TW (1) | TW202003586A (es) |
UY (1) | UY38177A (es) |
WO (1) | WO2019199685A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3015660A1 (en) * | 2016-03-04 | 2017-09-08 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for modulating body weight |
MA52205A (fr) | 2018-04-09 | 2021-02-17 | Amgen Inc | Protéines de fusion du facteur de différenciation de croissance 15 |
CA3131912A1 (en) * | 2019-03-08 | 2020-09-17 | Amgen Inc. | Growth differentiation factor 15 combination therapy |
KR20200124176A (ko) * | 2019-04-23 | 2020-11-02 | 주식회사 엘지화학 | 면역글로불린의 Fc 영역 및 GDF15를 포함하는 융합 폴리펩타이드 |
TW202140525A (zh) * | 2020-01-08 | 2021-11-01 | 大陸商上海翰森生物醫藥科技有限公司 | Fgf21突變體蛋白及其融合蛋白 |
WO2022092915A1 (ko) * | 2020-10-30 | 2022-05-05 | 가톨릭대학교 산학협력단 | Gdf15를 유효성분으로 함유하는 면역질환의 예방 및 치료용 조성물 |
WO2023025123A1 (zh) * | 2021-08-24 | 2023-03-02 | 广东东阳光药业有限公司 | Gdf15融合蛋白及其用途 |
WO2023154953A1 (en) | 2022-02-14 | 2023-08-17 | Ngm Biopharmaceuticals, Inc. | Gdf15 polypeptides for treating and preventing autoimmune diseases |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
US4615885A (en) | 1983-11-01 | 1986-10-07 | Terumo Kabushiki Kaisha | Pharmaceutical composition containing urokinase |
WO1993015722A1 (en) | 1992-02-07 | 1993-08-19 | Syntex (Usa) Inc. | Controlled delivery of pharmaceuticals from preformed porous microparticles |
WO1999006445A1 (en) | 1997-07-31 | 1999-02-11 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-15 |
BR0007414A (pt) | 1999-01-07 | 2001-10-16 | Lexigen Pharm Corp | Expressão e exportação de proteìnas antiobesidade como proteìnas de fusão fc |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US20030103978A1 (en) | 2000-02-23 | 2003-06-05 | Amgen Inc. | Selective binding agents of osteoprotegerin binding protein |
MXPA03005036A (es) | 2000-12-07 | 2003-09-05 | Lilly Co Eli | Proteinas de fusion glp-1. |
WO2002072608A2 (en) | 2001-03-09 | 2002-09-19 | University Of Chicago | POLYMERIC IMMUNOGLOBULIN FUSION PROTEINS THAT TARGET LOW-AFFINITY FCηRECEPTORS |
JP4422949B2 (ja) | 2001-06-26 | 2010-03-03 | 武田薬品工業株式会社 | TGF−βスーパーファミリー産生・分泌促進剤 |
US7332474B2 (en) | 2001-10-11 | 2008-02-19 | Amgen Inc. | Peptides and related compounds having thrombopoietic activity |
US7101852B2 (en) | 2003-05-30 | 2006-09-05 | The Board Of Regents Of The University Of Texas System | Composition and method for treatment and prevention of restenosis |
WO2005063815A2 (en) | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
EP1682582B1 (en) | 2003-11-13 | 2011-08-31 | Hanmi Holdings Co., Ltd | Method for the mass production of immunoglobulin constant region |
US20050249723A1 (en) | 2003-12-22 | 2005-11-10 | Xencor, Inc. | Fc polypeptides with novel Fc ligand binding sites |
PL2441466T3 (pl) | 2004-04-13 | 2015-01-30 | St Vincents Hospital Sydney Ltd | Środek hamujący MIC-1 |
US20090042780A1 (en) | 2004-05-20 | 2009-02-12 | Acceleron Pharma Inc | Modified TGF-Beta Superfamily Polypeptides and Related Methods |
US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
WO2007041635A2 (en) | 2005-10-03 | 2007-04-12 | Xencor, Inc. | Fc variants with optimized fc receptor binding properties |
CN1974601A (zh) | 2005-11-28 | 2007-06-06 | 上海新生源医药研究有限公司 | 一种新型Fc融合蛋白及其生产方法 |
CA2666599A1 (en) | 2006-08-18 | 2008-02-21 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
AU2008286706B2 (en) | 2007-08-16 | 2014-03-06 | Garvan Institute Of Medical Research | Agents and methods for modulating macrophage inhibitory cytokine (MIC-1) activity |
US8592562B2 (en) | 2008-01-07 | 2013-11-26 | Amgen Inc. | Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects |
WO2009141357A1 (en) | 2008-05-20 | 2009-11-26 | Roche Diagnostics Gmbh | Gdf-15 as biomarker in type 1 diabetes |
RU2509774C2 (ru) | 2008-08-04 | 2014-03-20 | Файв Прайм Терапьютикс, Инк. | Мутеины кислотной зоны внеклеточного домена рецептора фактора роста фибробластов |
CA2740632A1 (en) | 2008-10-31 | 2010-05-06 | St. Vincent's Hospital Sydney Limited | Methods of prognosis in chronic kidney disease |
MX340971B (es) | 2009-11-23 | 2016-08-02 | Amgen Inc * | Fragmento cristalizable (fc) de anticuerpo monomerico. |
WO2011064758A2 (en) | 2009-11-30 | 2011-06-03 | Pfizer Limited | Fusion protein |
EP2506861A1 (en) | 2009-12-02 | 2012-10-10 | Amgen Inc. | Binding proteins that bind to human fgfr1c, human b-klotho and both human fgfr1c and human b-klotho |
US8362210B2 (en) | 2010-01-19 | 2013-01-29 | Xencor, Inc. | Antibody variants with enhanced complement activity |
JP2013531030A (ja) | 2010-07-12 | 2013-08-01 | ファイザー・リミテッド | 電位開口型ナトリウムチャネルの阻害剤としてのn−スルホニルベンズアミド |
EP2593433B1 (en) | 2010-07-12 | 2014-11-26 | Pfizer Limited | N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels |
WO2012007868A2 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
EP2609427B1 (en) | 2010-08-26 | 2015-01-21 | Roche Diagnostics GmbH | Use of biomarkers in the assessment of the early transition from arterial hypertension to heart failure |
EP2439535A1 (en) | 2010-10-07 | 2012-04-11 | F. Hoffmann-La Roche AG | Diagnosis of diabetes related heart disease and GDF-15 and Troponin as predictors for the development of type 2 diabetes mellitus |
EP2635607B1 (en) | 2010-11-05 | 2019-09-04 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
ES2668895T3 (es) | 2011-03-16 | 2018-05-23 | Amgen Inc. | Variantes de Fc |
JP5977814B2 (ja) | 2011-04-08 | 2016-08-24 | アムジエン・インコーポレーテツド | 増殖分化因子15(gdf−15)を使用して代謝障害を治療または改善する方法 |
EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
KR20140125803A (ko) | 2012-01-26 | 2014-10-29 | 암젠 인크 | 성장 분화 인자 15(gdf-15) 폴리펩타이드들 |
CA2862516C (en) | 2012-03-27 | 2023-02-14 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
EA035344B1 (ru) | 2012-04-20 | 2020-05-29 | Мерюс Н.В. | Способ получения двух антител из одной клетки-хозяина |
MX370720B (es) | 2012-12-21 | 2019-12-20 | Aveo Pharmaceuticals Inc | Anticuerpos anti-gdf15. |
US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
RU2704285C2 (ru) | 2013-01-30 | 2019-10-25 | Нгм Байофармасьютикалз, Инк. | Композиции и способы применения для лечения метаболических расстройств |
JP6509852B2 (ja) | 2013-07-31 | 2019-05-08 | アムジエン・インコーポレーテツド | 増殖分化因子15(gdf−15)の構築物 |
US20170107248A1 (en) | 2014-06-23 | 2017-04-20 | Novartis Ag | Site specific protein modifications |
US20170204149A1 (en) | 2014-06-23 | 2017-07-20 | Novartis Ag | Hsa-gdf-15 fusion polypeptide and use thereof |
US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
CN106459222A (zh) | 2014-06-24 | 2017-02-22 | 诺和诺德股份有限公司 | Mic‑1融合蛋白及其用途 |
EP3174894B1 (en) | 2014-07-30 | 2021-06-23 | NGM Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
MY186702A (en) | 2014-10-31 | 2021-08-11 | Ngm Biopharmaceuticals Inc | Compositions and methods of use for treating metabolic disorders |
US20190000923A1 (en) | 2015-12-22 | 2019-01-03 | Novartis Ag | Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
CA3015660A1 (en) | 2016-03-04 | 2017-09-08 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for modulating body weight |
US10336812B2 (en) | 2016-05-10 | 2019-07-02 | Janssen Biotech, Inc. | GDF15 fusion proteins and uses thereof |
TW201741333A (zh) | 2016-05-24 | 2017-12-01 | 諾佛 儂迪克股份有限公司 | Mic-1化合物及其用途 |
TWI724392B (zh) | 2018-04-06 | 2021-04-11 | 美商美國禮來大藥廠 | 生長分化因子15促效劑化合物及其使用方法 |
MA52205A (fr) | 2018-04-09 | 2021-02-17 | Amgen Inc | Protéines de fusion du facteur de différenciation de croissance 15 |
CA3131912A1 (en) | 2019-03-08 | 2020-09-17 | Amgen Inc. | Growth differentiation factor 15 combination therapy |
-
2019
- 2019-04-08 MA MA052205A patent/MA52205A/fr unknown
- 2019-04-08 JO JOP/2020/0258A patent/JOP20200258A1/ar unknown
- 2019-04-08 WO PCT/US2019/026369 patent/WO2019199685A1/en unknown
- 2019-04-08 CA CA3096097A patent/CA3096097A1/en active Pending
- 2019-04-08 CR CR20200510A patent/CR20200510A/es unknown
- 2019-04-08 EA EA202092419A patent/EA202092419A1/ru unknown
- 2019-04-08 BR BR112020020823-0A patent/BR112020020823A2/pt unknown
- 2019-04-08 US US16/620,029 patent/US12054527B2/en active Active
- 2019-04-08 KR KR1020207032157A patent/KR20200140878A/ko not_active Application Discontinuation
- 2019-04-08 AU AU2019253462A patent/AU2019253462A1/en active Pending
- 2019-04-08 SG SG11202009884YA patent/SG11202009884YA/en unknown
- 2019-04-08 JP JP2019562592A patent/JP7058670B2/ja active Active
- 2019-04-08 CN CN201980024728.9A patent/CN111954537A/zh active Pending
- 2019-04-08 MX MX2020010659A patent/MX2020010659A/es unknown
- 2019-04-08 EP EP19719403.8A patent/EP3773656A1/en active Pending
- 2019-04-08 PE PE2020001560A patent/PE20201350A1/es unknown
- 2019-04-09 TW TW108112268A patent/TW202003586A/zh unknown
- 2019-04-09 AR ARP190100931A patent/AR114476A1/es unknown
- 2019-04-09 UY UY0001038177A patent/UY38177A/es not_active Application Discontinuation
-
2020
- 2020-10-06 PH PH12020551655A patent/PH12020551655A1/en unknown
- 2020-10-07 CL CL2020002585A patent/CL2020002585A1/es unknown
- 2020-10-07 IL IL277842A patent/IL277842A/en unknown
- 2020-10-08 CO CONC2020/0012563A patent/CO2020012563A2/es unknown
-
2021
- 2021-01-14 US US17/148,761 patent/US11161889B2/en active Active
- 2021-10-05 US US17/494,001 patent/US20220017584A1/en not_active Abandoned
-
2022
- 2022-04-11 JP JP2022064965A patent/JP2022095856A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
SG11202009884YA (en) | 2020-11-27 |
JP2020533271A (ja) | 2020-11-19 |
MX2020010659A (es) | 2020-10-28 |
US20210147500A1 (en) | 2021-05-20 |
UY38177A (es) | 2019-07-31 |
IL277842A (en) | 2020-11-30 |
PH12020551655A1 (en) | 2021-07-26 |
EA202092419A1 (ru) | 2021-02-05 |
WO2019199685A1 (en) | 2019-10-17 |
CN111954537A (zh) | 2020-11-17 |
KR20200140878A (ko) | 2020-12-16 |
US11161889B2 (en) | 2021-11-02 |
US12054527B2 (en) | 2024-08-06 |
JP2022095856A (ja) | 2022-06-28 |
US20230143988A1 (en) | 2023-05-11 |
CL2020002585A1 (es) | 2020-12-04 |
PE20201350A1 (es) | 2020-11-30 |
EP3773656A1 (en) | 2021-02-17 |
CA3096097A1 (en) | 2019-10-17 |
JOP20200258A1 (ar) | 2020-10-11 |
JP7058670B2 (ja) | 2022-04-22 |
US20220017584A1 (en) | 2022-01-20 |
TW202003586A (zh) | 2020-01-16 |
AR114476A1 (es) | 2020-09-09 |
MA52205A (fr) | 2021-02-17 |
AU2019253462A1 (en) | 2020-11-26 |
CR20200510A (es) | 2020-11-26 |
BR112020020823A2 (pt) | 2021-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2020012563A2 (es) | Proteínas de fusión del factor de diferenciación de crecimiento 15 | |
CL2018003148A1 (es) | Proteínas de fusión y usos de las mismas. | |
CL2022000036A1 (es) | Polipéptidos modificados y usos de los mismos (divisional de solicitud no. 201900261) | |
CL2016000249A1 (es) | Construcciones del factor de diferenciación de crecimiento 15 (gdf-15) | |
CL2020000810A1 (es) | Proteínas de fusión que comprenden enzimas de terapia de reemplazo de enzimas. | |
EA201790895A1 (ru) | Модифицированные полипептиды fgf-21 и их применение | |
AR102522A1 (es) | Variantes de región fc con propiedades modificadas de unión a fcrn y proteína a | |
UY37829A (es) | Muteínas de interleucina 21 y métodos de tratamiento | |
ECSP20081591A (es) | Proteínas de fusión que comprenden progranulina | |
EA201990229A1 (ru) | Новый ботулинический нейротоксин и его производные | |
CL2018002687A1 (es) | Proteínas de unión y métodos de uso de las mismas | |
UY36304A (es) | Proteínas de fusión, bacterias recombinantes y métodos de uso de las bacterias recombinantes | |
GT201400055A (es) | Proteínas de fusión para tratar trastornos metabolicos | |
CL2021000987A1 (es) | Proteínas de fusión del péptido similar al glucagón 1 (glp1)-factor de diferenciación del crecimiento 15 (gdf15) y usos de las mismas. | |
DOP2016000220A (es) | PROTEÍNAS DE FUSIÓN TATk-CDKL5, COMPOSICIONES, FORMULACIONES Y USO DE ESTAS. | |
CO2021014413A2 (es) | Polipéptido de fusión que comprende región fc de inmunoglobulina y gdf15 | |
CL2021000849A1 (es) | Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos (divisional de la solicitud no. 201900999) | |
ECSP17075380A (es) | Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos | |
CL2020000733A1 (es) | Proteína de fusión que comprende una porción de fgf-18. | |
PE20190966A1 (es) | Factor viii direccionado a los globulos rojos y metodo para su uso | |
CO2023001488A2 (es) | Proteínas de fusión del ligando para flt3 y métodos de uso | |
CL2019003459A1 (es) | Métodos de cultivo celular. | |
CL2016003317A1 (es) | Anticuerpos biespecificos anti-il4-il13 | |
AR087640A1 (es) | Proteina de fusion acortada de tetranectina-apolipoproteina a-i, una particula lipidica que la contiene, y usos de la misma | |
AR115565A1 (es) | Proteínas de fusión que comprenden progranulina |